Search Results for “diagnostic” – Page 61 – media

Manufacturing hiccup in China trips up Sanofi’s vaccine sales momentum

After a strong 2017, Sanofi Pasteur got off to a less-than-stellar start this year. In China, inspectors put a temporary kibosh on imports of the pediatric shot Pentaxim, thanks to vaccine batches that failed to pass inspection. That move hobbled the shot's sales—and dragged the rest of the unit down, too.
- Source: fiercepharma
- 630
- May 2, 2018
Company Insights Pentaxim Sanofi
Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for its new liquid biopsy assay, which is an expanded version of its FoundationACT® assay. The new assay will include more than 70 genes and genomic biomarkers for microsatellite instability (MSI) and blood tumor mutational burden (bTMB). If approved, this test could be the first FDA-approved liquid biopsy assay to incorporate multiple companion diagnostics (CDx) and multiple biomarkers to inform the use of targeted oncology therapies, including immunotherapies.
- Source: nvestors.foundationmedicine
- 585
- April 27, 2018
FDA liquid biopsy assay microsatellite instability
mHealth app for clinical decision support improves diagnosis time, test ordering

Mobile health (mHealth) applications for clinical decision support could improve physicians’ test ordering and diagnosis decisions, according to a study published April 20 in the Journal of Informatics in Health and Biomedicine.
- Source: Clinical Innovation
- 628
- April 27, 2018
Clinical mHealth Researches
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for LYNPARZA®(olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018.
- Source: businesswire
- 876
- April 17, 2018
AstraZeneca breast cancer Clinical Trials Merk
New blood pressure guidelines could put lives at risk, say experts

A new report in JAMA Internal Medicine by University of Sydney and Bond University scholars weighs the risks and benefits of a recent change to blood pressure guidelines in the US.
- Source: MedicalXpress
- 561
- April 17, 2018
blood pressure Policies
Portable Cancer-Detecting Device Being Developed By Korean Startup

To diagnose cancer, doctors use a bunch of complex examinations like an MRI, a CT scan, a biopsy or a lengthy blood test. Because of the sophisticated machines and equipment needed for these techniques and procedures, they are only conducted in the hospital setting. One startup is about to change this with its portable cancer-detecting device.
- Source: International Business Times
- 1,962
- April 13, 2018
cancer medical device Researches
Blockchain System Aims to Identify Health Problems Using AI

A new Blockchain platform has seemingly proven that it is possible to for AI to perform more accurate health diagnosis than human doctors, paving the way for a change in the way medical tests are performed.
- Source: Cointelegraph
- 662
- April 12, 2018
AI digital health Market Views
FDA Approves Rucaparib for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On April 6, 2018, the Food and Drug Administration(FDA) approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- Source: asco.org
- 537
- April 11, 2018
FDA New Approvals rucaparib
Eidos Therapeutics completes $64M Series B financing

Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials
- Source: prnewswire
- 598
- April 10, 2018
amyloidosis Series transthyretin
Where AI has the most promise for reducing healthcare costs

AI technology is already in use in certain aspects of healthcare, such as diagnostic imaging, but it’s being underutilized in several others.
- Source: HealthcareITNews
- 723
- April 10, 2018
AI digital health EHR Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.